News & Analysis as of

Digital Health Life Sciences Investment

Wilson Sonsini Goodrich & Rosati

The Life Sciences Report – June 2025

This latest edition features articles on succeeding in the current life sciences funding market, strategic and legal considerations in digital health combinations, the corporate practice of medicine and guidance for...more

A&O Shearman

The future of the robotics metaverse in the healthcare sector

A&O Shearman on

On 26 February 2025, the European Economic and Social Committee (EESC) adopted an opinion addressing the integration of robotics and the metaverse in healthcare. This forward-looking document outlines the opportunities and...more

A&O Shearman

New German government: Key plans for the Life Sciences and Healthcare sector

A&O Shearman on

Following the election in February, the party leaderships of CDU, CSU and SPD have agreed on a coalition agreement titled “Responsibility for Germany”. The 146-page document also sets out aspects regarding the healthcare and...more

Orrick, Herrington & Sutcliffe LLP

Telehealth Transformation: Innovating Mental Health Care Life Sciences Snapshot – Q1 2025

Q4 2024 marked the conclusion of a turnaround year for life sciences venture investment. After two consecutive years of declining activity and macroeconomic uncertainty, the dust has settled, and investment is back on the...more

Fenwick & West Life Sciences Group

In 2024, the Digital Health Revolution Continues

Digital health is showing signs of life despite financial markets that seem determined to bring some of 2023’s volatility into the new year. Stocks are up and down, and bond yields are climbing. Inflation is proving stubborn,...more

McDermott Will & Schulte

European Health & Life Sciences Symposium 2023 | Key Takeaways

McDermott Will & Schulte on

200+ leading individuals in healthcare, life sciences and private equity gathered at the Shangri-La Hotel in Paris for the European Health & Life Sciences Symposium 2023 to enjoy a day packed with fireside chats, in-depth...more

Fenwick & West Life Sciences Group

Rock Health Summit Takeaway: Digital Health is Rightsizing, Not Retreating

From its inception, digital health has been focused on developing technologies and solutions that offer a higher quality of healthcare to more people at a lower cost. Amidst fluctuations in stock prices, valuations and...more

Knobbe Martens

Venture Capitalist Funding in Medtech Increasing

Knobbe Martens on

Recent reports, including one by PitchBook, indicate that both venture capitalist funding for medtech companies and the variety of medtech companies receiving venture capitalist funding has increased since the first quarter...more

Bass, Berry & Sims PLC

Healthcare Trends & Transactions Q2 2023

Bass, Berry & Sims PLC on

The healthcare M&A market appears to be steadying. Although deal activity through the year appears slightly below the high-water marks for the corresponding period of 2022, deal activity is generally up from the first quarter...more

McDermott Will & Schulte

HPE Europe 2022 | Key Takeaways

Key Trends & Opportunities in Life Sciences and Healthcare Investing - The current macroeconomic environment is creating challenges for healthcare and life sciences businesses, which have been impacted hard by wage...more

Bass, Berry & Sims PLC

Healthcare Transactions Q3 2022

Bass, Berry & Sims PLC on

Although healthcare M&A activity in Q3 declined slightly from the previous quarter, analysts believe the activity level declined much less than expected given the numerous headwinds—inflation, rising interest rates, labor...more

Orrick, Herrington & Sutcliffe LLP

Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q4 2022

This report series examines quarterly trends in life sciences venture investment. Key findings for Q3 2022 include: • The industry generated $6.2 billion in deal value across 352 deals in Q3, exhibiting further quarterly...more

Fenwick & West Life Sciences Group

Market Slowdown is Opportunity for Digital Health Companies to Hone Focus, Deliver Bold Yet Tenable Plans

There are more investors in digital health today than there have ever been, but the questions they are posing to company founders before writing a check are tougher than they were just a year ago....more

Fenwick & West Life Sciences Group

Digital Health Has Strong Fundamentals to Pull Through Downturn

Digital health has been a powerhouse investment sector since it emerged more than a decade ago. Year-after-year, startups consistently demonstrate their innovations bring real-world benefits and our healthcare system...more

Bass, Berry & Sims PLC

Healthcare Transactions Q1 2022

Bass, Berry & Sims PLC on

2022 started strong for healthcare transactions with some reports suggesting a record-breaking January. Although deal activity cooled in February and March, transaction pipelines still indicate that 2022 is on pace to match...more

Fenwick & West Life Sciences Group

Economic Conditions Changing, but Digital Health Still Strong

The digital health sector emerged as a juggernaut during the COVID-19 pandemic, with almost $15 billion invested in privately-held digital health companies in 2020 and nearly $30 billion invested last year, according to our...more

Fenwick & West Life Sciences Group

The Most-Funded Year Ever for Digital Health Startups – New Trends, Opportunities Emerge in Q3

At the end of Q3, aggregate funding raised by digital health startups in 2021 surpassed $20 billion. Although 2021 continues to be a record-breaking year for digital health startups, investors gently tapped the breaks in Q3....more

Fenwick & West Life Sciences Group

Digital Health Trends Shaping 2021: The Move to Telemedicine 2.0

Digital health companies and investors had a remarkable 2020, as fundraising totals broke records and deal volume significantly outpaced previous years. Moreover, the increase in investment activity has triggered more exit...more

McDermott Will & Schulte

Life Sciences Dealmaking Symposium: Powering through the Pandemic: Trends in Early-Stage Investment

McDermott Will & Schulte on

The pursuit of progress during these unprecedented times has led to a surge in life sciences investment and funding for early stage companies. Investors are on the lookout for the next big innovation while also navigating new...more

McDermott Will & Schulte

BVCA Healthcare Sector Forum 2020: Rounding Up

McDermott was delighted to partner with the BVCA (British Venture Capital Association) on its recent virtual Sector Forum Series: Healthcare event. The event gathered industry experts – from entrepreneurs, to investors and...more

Fenwick & West Life Sciences Group

Rock Health Summit 2020 Takeaways: Digital Health Is Firing on All Cylinders

When investors survey the digital health sector today, they see nearly every number trending upward. There is more deal volume than VCs have seen in past years, with the third quarter of 2020 outpacing anything they’ve...more

Orrick, Herrington & Sutcliffe LLP

Investments in Germany under COVID 19 – Turning Crises into Opportunity

The COVID-19 pandemic has already been declared as history's gravest economic crisis. Chancellor Angela Merkel described the current situation as "the most challenging crisis we have faced since the Second World War." But...more

Fenwick & West Life Sciences Group

Digital Health Investors Offer Cautious Optimism at Rock Health H1 2020 Event

Venture investors are pleased to see digital health companies continue to transform the healthcare system despite unprecedented challenges brought by the COVID-19 pandemic....more

McDermott Will & Schulte

What is the Impact of Recent Regulation and Government Measures on Investments in Healthcare and Life Sciences in Europe?

In the fourth installment of McDermott’s HPE Europe Summer Webinar Series 2020: What’s the Impact of Recent Regulation and Government Measures on Investments in Healthcare and Life Sciences in Europe? moderator and McDermott...more

Fenwick & West Life Sciences Group

Biotech & Life Sciences Trends to Consider Following JPM 2020: M&A, Venture Capital and More

The annual gathering of life sciences executives and investors in San Francisco that many now call “JPM Week” recently concluded, marking the J.P. Morgan Healthcare Conference’s 38th year....more

37 Results
 / 
View per page
Page: of 2

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide